Dundee Corp DNDEF

Dundee Corporation Portfolio Holding, TauRx Pharmaceuticals

[HRc60to65]

DC.a is holding 3.7% of TauRx Pharmaceuticals with a book value of 36.216M$CDN

In Q2-2022, DC.a is valuating TauRx at 1B$CDN.

DC.a has 88,125,373 shares issued and outstanding. 
TauRx is 0.41$/DC.a share and it is for free.

If TauRx “Lucidity” drug get positive results TauRx will do public IPO.  The TauRx value can reach 5B$US to 10B$US or 2.5$CDN to 5.0$CDN per DC.a share.

At the actual DC.a stock price of around 1.30$CDN TauRx potential is free.

[Catscratch]

Dundee has several irons in the fire.    In addition to TauRx, other examples include UHIC, Android or any of the mining investments.   It really only takes one or two of these investments to be successful to justify Dundee's current market cap. If Jonathan and Board can continue to establish a track record of thoughtful capital allocation while consistently growing NAV